| May 12 2020 |
CARES Act: Impact of revised net operating loss rules in M&A transactions |
Godfrey & Kahn S.C. |
| May 8 2020 |
A Secret They Don’t Want to Keep: Buyer Sought to Terminate Deal for Victoria’s Secret |
Godfrey & Kahn S.C. |
| May 7 2020 |
Does the Coronavirus Change the Material Adverse Event Clause for Mergers & Acquisitions? |
Mintz |
| May 7 2020 |
COVID-19 Update: Antitrust Enforcement Remains Robust Despite COVID-19 |
Cadwalader, Wickersham & Taft LLP |
| May 6 2020 |
Energy & Sustainability M&A Activity – May 2020 |
Mintz |
| May 5 2020 |
COVID-19: Distressed M&A in the Era of a Pandemic |
K&L Gates LLP |
| May 4 2020 |
Recent Decision in Newmont Mining Reinforces the High Bar Buyers Face when Attempting to Establish a Material Adverse Event |
Mintz |
| Apr 30 2020 |
COVID-19 and Poison Pills: The Right Prescription? |
Mintz |
| Apr 30 2020 |
COVID-19: Proposed Legislation Would Prohibit Many Mergers and Acquisitions During Pandemic |
K&L Gates LLP |
| Apr 30 2020 |
Court of Chancery Applies Entire Fairness Standard to PennyMac’s Reorganization Transaction |
K&L Gates LLP |
| Apr 29 2020 |
How Antitrust Will Shape M&A During the Pandemic |
Foley & Lardner LLP |
| Apr 29 2020 |
COVID-19 Impacts on the Copyright Office: What Does It Mean for Mergers and Acquisitions? |
Faegre Drinker |
| Apr 27 2020 |
Is a Moratorium on Mergers During the Pandemic a Bridge Too Far? |
MoginRubin |
| Apr 24 2020 |
M&A in the Investment Services Space – Help! My Deal Went Sideways… |
Norris McLaughlin P.A. |
| Apr 22 2020 |
In Application of American Express to Horizontal Merger Challenge, District Court Allows Merger of Airline Ticket Platforms |
Mintz |
| Apr 22 2020 |
United Technologies/Raytheon Highlights Key Issues in Aerospace and Defense Industry Merger Review |
McDermott Will & Emery |
| Apr 21 2020 |
Poison Pills, NOL Poison Pills and the COVID-19 Pandemic |
Robinson & Cole LLP |
| Apr 16 2020 |
Revisiting Guidance on MFN Terms |
Cornerstone Research |
| Apr 16 2020 |
Force Majeure and Frustration in English Law M&A Agreements in the Context of COVID-19 |
Katten |
| Apr 15 2020 |
How Will COVID-19 Impact M&A? |
Robinson & Cole LLP |
| Apr 13 2020 |
Upcoming/New CFIUS Filing: ProSiebenSat.1 Media SE; General Atlantic Coöperatief U.A. and The Meet Group, Inc. |
Squire Patton Boggs (US) LLP |
| Apr 13 2020 |
CFIUS Clearance: Capgemini and Leidos Cyber |
Squire Patton Boggs (US) LLP |
| Apr 7 2020 |
Underestimated Risks: M&A and German Employee Inventions |
Squire Patton Boggs (US) LLP |
| Apr 1 2020 |
Is a Pandemic a Material Adverse Event or Change in M&A? |
MoginRubin |
| Apr 1 2020 |
Court Of Chancery Orders Specific Performance Of Merger Agreement, Finding That Fraud Contained In FDA Filings For Approval Of Target Product Did Not Rise To A “Material Adverse Effect” |
K&L Gates LLP |
| Apr 1 2020 |
In A Section 262 Appraisal Rights Proceeding, Chancery Court Accepts A Modified Version Of Petitioners’ Valuation Of A Merging Company’s Stock |
K&L Gates LLP |
| Mar 31 2020 |
Quarantining Deal Risk in the COVID-19 ERA: A Buyer's Checklist |
McDermott Will & Emery |
| Mar 30 2020 |
Navigating the Pandemonium Raised by the Pandemic: Risk Mitigation in M&A |
Bracewell LLP |
| Mar 28 2020 |
U.K. Begins Phase II Probe of Cengage/McGraw-Hill Merger |
MoginRubin |
| Mar 26 2020 |
UPDATE - COVID-19: A Material Adverse Change in the UK? |
Greenberg Traurig, LLP |
| Mar 25 2020 |
COVID-19: A Material Adverse Change in the UK? |
Greenberg Traurig, LLP |
| Mar 25 2020 |
Coronavirus Disease (COVID-19) – Financing and M&A Agreements in Poland |
Greenberg Traurig, LLP |
| Mar 25 2020 |
Short-term Hiccup or Significant Long-term Effect? Material Adverse Effect Clauses and the COVID-19 Pandemic |
Pierce Atwood LLP |
| Mar 24 2020 |
COVID-19: M&A, Commercial Finance and General Contract Considerations |
Vedder Price |
| Mar 23 2020 |
Cengage Learning and McGraw-Hill : CMA Ultimatum Comes Same Day U.S. reps urge DOJ scrutiny |
MoginRubin |
